| The rise of Parkinson’s disease is a disturbing trend in global health. Following Alzheimer’s disease, Parkinson’s disease (PD) is the second-most common neurodegenerative disease in the United States. According to Dr. Ray Dorsey, a neurologist at the University of Rochester Medical Center, “Parkison’s is the fastest-growing neurological disorder in the world. In the United States, the number of people with Parkinson’s has increased 35% in the last 10 years”. This company’s subsidiary developed a generic transdermal form of dopamine treatment for Parkinson’s. This patch, similar to a nicotine patch, can help ease motor symptoms of Parkinson’s, and potentially help with several non-motor symptoms. Let us explain: 
Parkinson’s disease is a disorder of the nervous system that causes difficulties with movement, muscle control, and balance. Non-motor-related symptoms include cognitive impairment, mood and behavioral problems, sleep disorders, and constipation. The National Institute of Neurological Disorders and Stroke (NINDS) estimates that nearly 500,00 Americans have been diagnosed with the disease. Some experts believe the number is closer to one million due to undiagnosed individuals. The NINDS estimates that the cost of treating PD is approximately $14 billion annually with indirect costs estimated conservatively at $6.3 billion.
Basically, our nervous system is made up of individual cells which serve as a “communication network”. Neurons use chemical messengers called neurotransmitters. In this case, dopamine is the critical agent that transmits messages from the brain to the muscle. PD impacts the body’s ability to generate this substance.
Muhammed Ali and, Michael J. Fox, and Robin Williams are just a few names to see their quality of life destroyed by this terrible disease. This company ’has developed a generic transdermal patch- a drug delivery system that is applied directly to the skin- that has been used worldwide as an alternative to conventional oral treatment. The patch activates dopamine receptors. Once administered, it can bind the receptors to the brain and mimic the action of dopamine. This company received encouraging study results for its patch development program. It will advance the trial studies to pivotal human tests. Results are expected by the end of the year. The company has embarked on the development of a started ramping up commercial production facilityies to meet anticipated demand. This company is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities. The company focuses on precision transdermal and oral dissolvable drug formulations, low-cost infectious diseases, and oral health screening tests, emerging active pharmaceutical ingredients for neurological applications including psychedelic and cannabis compounds. The generic drug delivery model represents a major opportunity for scalable value creation through expedited clinical evaluation and product launch. Click here to learn more about this company’s PD treatments and other opportunities it is pursuing in the pharmaceutical space. | 
No comments:
Post a Comment